by Raynovich Rod | Feb 14, 2018 | Biopharmaceuticals
Update-1 …2/17/18 Good Week for Biotech: FBT up 6.29%, IBB up 4.44%, XBI up 6.26% Biotech stocks continued their strong recovery from the big sell-off in the prior week but about 3% under 2018 highs. Biotech ETFs tracked the QQQ up 5.68% for the week but biotech...
by Raynovich Rod | Feb 12, 2018 | Biopharmaceuticals
Large Cap Biopharmaceuticals Performance Part 1- After Correction Technicals: we are holding the December 2017 bottom but 2018 gains on some indices have been wiped out with peak values on Jan. 26. The FBT was the top performing ETF in 2018 YTD. Many of our picks have...
by Raynovich Rod | Feb 4, 2018 | Biopharmaceuticals
Updates-2… 2/6/18 Biotechs Down With Overall Market Over 5 Days Closing Prices as of 2/6/18 XBI up 3% at $91.05 down 5.34% over 5 days IBB up 2% at $109.36 down 7.35% over 5 days QQQ up 2.65% at $162.31 down 5.04% over 5 days By now you have read about all the...
by Raynovich Rod | Jan 2, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Rayno Life Science Portfolio
2/28/18 Update Tape looks sluggish at major resistance. Downgrade to HOLD on Celgene (CELG). Bad regulatory news on relapsing multiple sclerosis drug ozanimod. 2/2/18 Update After Sell-Off Cautious on Amgen (AMGN) after earnings release but looks better than the IBB...
by Raynovich Rod | Dec 20, 2017 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Clinical Diagnostics and Tools: Big Winners Are In Genomics and Personalized Medicine Slower growth in routine clinical diagnostics, tools are favored. Hologic has a unique business model for women’s health and diagnostics. Gene sequencing is important for...
by Raynovich Rod | Nov 29, 2017 | Biopharmaceuticals, Life Science ETF's and Mutual Funds, Macro
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK...
by Raynovich Rod | Nov 20, 2017 | Biopharmaceuticals
11/29/17 Market Reversal in Early Trading 11:35a -FAANG sell-off Stocks show a rotation out of technology and into financials and cyclical consumer goods. XLK is down 2.2%, XLV up 0.66%, IBB up 0.42% with large caps holding. 11/28/17 Biotechs Treading Water But Many...
by Raynovich Rod | Nov 16, 2017 | Biopharmaceuticals
Biotech Correction: Sell-Off Has Reached 10% over Three Months Biotechs under pressure-has revenue growth slowed? Technicals-a break through bottom channel. Need a bounce today. Celgene is a bellwether. A buy in the $102 range. Biotech stocks have been weak since Q4...
by Raynovich Rod | Nov 1, 2017 | Biopharmaceuticals
BioBeat Market Update…Technicals Firming Up 11/3/17 11am A lot of green screen today so time to nibble but I would prefer to pick stocks rather than play the ETF game. Recent trades we made are: sell XBI at $87, buy PFE at $35 and today buy CELG at $100. No...
by Raynovich Rod | Jul 19, 2017 | Biopharmaceuticals
Update-1… JY 19…Biotech and Healthcare Stocks Continue to Rally IBB breaks through top to $322.92 up 21.68% YTD; XBI up 1.34% today 35.4% YTD; XLV up 17.6% YTD. Rayno Life Science top winners YTD: ABBV up 18.19%, AMGN up 22.6%, BLUE up 55% YTD, FMI up...